ACC.19: 3 Studies in Cardioprotection

March 25, 2019
Veronica Hackethal, MD
Veronica Hackethal, MD

Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.